Neoadjuvant Therapy and Axillary Lymph Node Status in HER2-Positive Breast Cancer.

IF 1.8 4区医学 Q3 ONCOLOGY

Cancer Investigation Pub Date : 2023-07-01 DOI:10.1080/07357907.2023.2238312

Sabine Danzinger, Christian Pfeifer, Sophia Wimmer, Kristina Tendl-Schulz, Christian F Singer

引用次数: 0

Abstract

Based on an estimating model, the aim of our study was to evaluate the axillary lymph node involvement of patients with primary invasive early human epidermal growth factor receptor 2 (HER2)-positive breast cancer before receiving neoadjuvant therapy (NAT). Patients with primary surgery (n = 63) were compared with patients who had received NAT (combined chemo/HER2-targeted antibody therapy) before surgery (n = 152). In patients receiving NAT, a positive N stage was estimated in 73.2 (49.8%) tumors resulting in a conversion (positive N stage-ypNpositive) of 35.5%. In 126 cases with ypN0 stage, a positive N stage was estimated in 41.4%.

查看原文本刊更多论文

her2阳性乳腺癌的新辅助治疗和腋窝淋巴结状态。

基于一个估计模型，我们的研究目的是评估原发性侵袭性早期人表皮生长因子受体2 (HER2)阳性乳腺癌患者在接受新辅助治疗(NAT)前腋窝淋巴结的累及情况。首次手术患者(n = 63)与术前接受过NAT(联合化疗/ her2靶向抗体治疗)的患者(n = 152)进行比较。在接受NAT治疗的患者中，估计有73.2例(49.8%)肿瘤呈阳性N期，导致35.5%的肿瘤转化(阳性N期- ypn阳性)。126例ypN0期患者中，估计有41.4%为N阳性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Investigation 医学-肿瘤学

CiteScore

3.80

自引率

4.20%

发文量

审稿时长

8.5 months

期刊介绍： Cancer Investigation is one of the most highly regarded and recognized journals in the field of basic and clinical oncology. It is designed to give physicians a comprehensive resource on the current state of progress in the cancer field as well as a broad background of reliable information necessary for effective decision making. In addition to presenting original papers of fundamental significance, it also publishes reviews, essays, specialized presentations of controversies, considerations of new technologies and their applications to specific laboratory problems, discussions of public issues, miniseries on major topics, new and experimental drugs and therapies, and an innovative letters to the editor section. One of the unique features of the journal is its departmentalized editorial sections reporting on more than 30 subject categories covering the broad spectrum of specialized areas that together comprise the field of oncology. Edited by leading physicians and research scientists, these sections make Cancer Investigation the prime resource for clinicians seeking to make sense of the sometimes-overwhelming amount of information available throughout the field. In addition to its peer-reviewed clinical research, the journal also features translational studies that bridge the gap between the laboratory and the clinic.